Date
- 2026 (1)
- 2025 (38)
- 2024 (86)
- 2023 (73)
- 2022 (59)
- 2021 (124)
- 2020 (107)
- 2019 (98)
- 2018 (95)
- 2017 (73)
- 2016 (12)
- 2015 (22)
- 2014 (19)
- 2013 (9)
- 2012 (8)
- 2011 (14)
- 2010 (27)
- 2009 (13)
- 2008 (5)
- 2007 (11)
- 2006 (8)
- 2005 (4)
- 2004 (8)
- 2003 (3)
- 2002 (10)
- 2001 (6)
- 2000 (20)
- 1999 (9)
- 1998 (12)
- 1997 (16)
- 1996 (8)
- 1995 (3)
- 1994 (31)
- 1993 (17)
- 1992 (5)
- 1991 (86)
Sponsor content
1140 result(s) found, displaying 291 to 300
-
Cancellation by sponsorRequested by Pfizer Australia Pty Ltd
-
Cancellation by sponsorRequested by Pfizer Australia Pty Ltd
-
Cancellation by sponsorRequested by Pfizer Australia Pty Ltd
-
Cancellation by sponsorRequested by Pfizer Australia Pty Ltd
-
Cancellation by sponsorRequested by Pfizer Australia Pty Ltd
-
Australian public assessment report (AusPar)Australian Public Assessment Report for BNT162b2 (mRNA)
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ZIRABEV bevacizumab 100 mg/ 4 mL concentrated solution for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ZIRABEV bevacizumab 400 mg/ 16 mL concentrated solution for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for LORVIQUA lorlatinib 100 mg tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for LORVIQUA lorlatinib 25 mg tablet blister pack.